"Spin-outs have become an increasingly prominent part of the life sciences industry. Pharma and big biotech are spinning out R&D assets to maximize their value and to boost their own development efforts. VCs and management teams are using spin-outs to access later-stage drug candidates and thereby to shorten development timelines and enhance the financeability of their companies. In this panel, we will hear veterans of spinouts describe their experiences with this mode of company building and financing. We will discuss recent trends in spinouts, financing approaches, IP issues, strategic concerns and the like."

Objective1: Consider and discuss recent trends in spin-outs.

Objective2:Discuss financing approaches.

Objective3:Identify and discuss potential issues in working with the strategic sponsors of the spin-out.